A weight loss marvel drug Rishi Sunak describes as a “game changer” will likely be prescribed to tens of 1000's in a bid to ease the nation’s well being disaster.

The injection curbs starvation and may also help sufferers lose 15 % of their physique weight.

During a £40million, two-year trial, specialist weight administration companies will likely be expanded so extra individuals get prescriptions.

The Prime Minister stated it'll assist these struggling to shed the kilos to stay more healthy lives, and minimize NHS ready lists by lowering demand for care.

He added: “Obesity puts huge pressure on the NHS. Using the latest drugs to support people to lose weight will be a game-changer by helping tackle dangerous obesity-related health conditions such as high blood ­pressure, diabetes and cancer.

READ MORE: Express launches campaign to get knighthoods for MND heroes Rob Burrow and Kevin Sinfield

“It will reduce pressure on ­hospitals, support people to live healthier and longer lives and help to deliver on my priority to cut NHS waiting lists.”

Watchdog Nice earlier this yr really helpful semaglutide, extra generally generally known as Wegovy, for adults with a physique mass index of not less than 35 and one weight-related well being situation corresponding to diabetes or hypertension.

However, it isn't but accessible within the UK attributable to provide constraints.

Manufacturer Novo Nordisk stated in May it was working to make Wegovy accessible as quickly as attainable.

Health officers are understood to be in shut discussions with the agency to safe provide for the pilot as quickly because the drug launches right here.

Nice suggested that NHS use must be restricted to specialist weight administration companies, that are largely hospital-based, which means solely round 35,000 ­individuals would be capable of entry it.

The trial will discover how ­companies might be expanded exterior of hospitals and GPs might ­prescribe the medication, guaranteeing tens of 1000's extra can profit.

Obesity is without doubt one of the greatest strains on the NHS and is a number one reason behind a number of extreme well being ­situations corresponding to heart problems, diabetes and most cancers.

It is estimated to value the well being service £6.5billion a yr. More than a million hospital ­admissions have been linked to the ­situation in 2019/20.

Latest information reveals 12 million adults within the UK are overweight, 28 % of the inhabitants in England, whereas an additional 16 million have been obese.

It signifies that round two-thirds of the grownup inhabitants are above a wholesome weight – outlined as having a BMI of 25 or above.

Delivered through a weekly injection, semaglutide targets an space of the mind that regulates urge for food and mimics a hormone that curbs ­starvation. It might be life-changing for sufferers corresponding to paramedic Alex Guevara. The father-of-three, from Milton Keynes, Buckinghamshire, minimize his weight from 20 to fifteen stone after receiving the remedy.

Alex, 47, stated: “I needed ­something dramatic to break the cycle and stop me hurtling towards type 2 diabetes, heart disease and stroke. I was also on medication for depression and asthma. I even felt suicidal.” Health Secretary Steve Barclay stated this subsequent ­era of weight problems medication had nice potential when ­prescribed alongside train, eating regimen and ­behavioural assist. He added: “This pilot will help people live longer, healthier lives.”

NHS medical director Professor Sir Stephen Powis stated weight problems “can have devastating consequences for the nation’s health”.

He added: “This pilot will help determine if these medicines can be used safely and effectively in non-hospital settings as well as with a range of other interventions we have in place.” Experts on Tuesday night time stated the drug’s wider use might have enormous advantages if carefully monitored and supplied alongside life-style recommendation.

Professor Kamila Hawthorne, chair of the Royal College of GPs, stated the enlargement was welcome however should be backed by “sufficient resource and funding to account for the increased workload”.

She added: “Shifting some of this care safely into primary care is worth exploring as it makes sense for patients to access care within the community.

“Any plans to expand availability of semaglutide in primary care must also be done based on ­evidence of long-term benefit to patients. And sufficient availability of the drug must be ensured ahead of any roll out, so as not to raise patients’ expectations – as there may be many people who need it.”

Professor Naveed Sattar, an knowledgeable in metabolic drugs on the University of Glasgow, stated: “Anything that helps more people living with obesity gain access to medicines that help them lose weight sustainably could be a major plus to health outcomes.”

Dr Duane Mellor, a registered ­dietitian and senior lecturer at Aston University, added: “It is really ­welcome that the government is investing in weight management services for people living with obesity.

“Hopefully this will go beyond focusing only on a drug and will include dietary, lifestyle and ­psychological support.”